Jakavi 15mg tablets |Ruxolitinib | MHP
JAKAVI 15MG DESCRIPTION Jakavi 15mg belongs to the classification of medications called anti-cancer drugs. Jakavi 15mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 15mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age. Jakavi 15mg tablet is prescription drug provided under supervision of medical oncologist. JAKAVI 15MG MECHANISM OF ACTION Ruxolitinib is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JAK...